Snapshot from Aug 02, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Persephoni invests in SelSym Biotech
Business investment partnership

Persephoni invests in SelSym Biotech

Analysis based on 6 articles · First reported Jul 15, 2026 · Last updated Jul 16, 2026

Sentiment
30
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

This investment highlights growing interest in innovative hemostatic therapies. While SelSym is preclinical, the partnership may accelerate development of SymClot, potentially impacting the trauma care market.

Biotechnology Medical Devices
Event Summary

Persephoni BioSciences, a global venture creation platform, announced that SelSym Biotech, a preclinical-stage company developing biomimetic therapies for hemorrhage and wound care, has joined its portfolio. SelSym's lead product, SymClot, is an injectable biomaterials-based therapeutic designed to mimic natural platelets. The investment marks SelSym's first equity financing and will support advancing SymClot toward clinical milestones. SelSym will operate out of Persephoni's Clinical Impact Studio in Research Triangle Park. The science originated from Dr. Ashley Brown's lab at North Carolina State University and has been validated in animal models.

Key Actions
90 Persephoni BioSciences invested in SelSym Biotech
80 SelSym Biotech joined portfolio of Persephoni BioSciences
Entities Involved
priv
SelSym Biotech
SelSym receives its first equity financing and strategic support from Persephoni, validating its technology and enabling progress toward clinical trials.
Importance 100.0 Sentiment 60.0
priv
Persephoni BioSciences
Persephoni adds SelSym to its portfolio, expanding its presence in hemostatic therapies.
Importance 80.0 Sentiment 40.0
per
Seeman
As co-founder and CEO of SelSym, Nandi leads the company through its first equity financing and strategic partnership.
Importance 40.0 Sentiment 30.0
per
Hilary Schultz
As CEO of Persephoni, Schultz announced the partnership, reinforcing her role in biotech venture creation.
Importance 30.0 Sentiment 20.0
per
Ashley Brown
Brown's lab at NC State originated the SymClot technology, which is now being advanced by SelSym.
Importance 30.0 Sentiment 20.0
per
Andrew Lyon
Co-founder of SelSym, contributing to the company's scientific foundation.
Importance 20.0 Sentiment 10.0
per
Thomas Barker
Co-founder of SelSym, contributing to the company's scientific foundation.
Importance 20.0 Sentiment 10.0
govactor
United States — National Institutes of Health
Provided non-dilutive grant funding to support SelSym's early development.
Importance 15.0 Sentiment 5.0
govactor
United States — United States Department of Defense
Provided non-dilutive grant funding to support SelSym's early development.
Importance 15.0 Sentiment 5.0
Relationships
United States — National Institutes of Health related ↔ United States — United States Department of Defense
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.